GeneDx (NASDAQ:WGS) Director Keith Meister Purchases 165,000 Shares of Stock

Posted by Francis Steltz on May 16th, 2026

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) Director Keith Meister purchased 165,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $39.09 per share, for a total transaction of $6,449,850.00. Following the transaction, the director directly owned 4,598,297 shares of the company’s stock, valued at approximately $179,747,429.73. This represents a 3.72% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

GeneDx Trading Up 4.9%

NASDAQ WGS opened at $40.75 on Friday. The stock’s 50-day simple moving average is $64.01 and its two-hundred day simple moving average is $102.00. GeneDx Holdings Corp. has a twelve month low of $32.21 and a twelve month high of $170.87. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.21 and a beta of 2.06.

GeneDx (NASDAQ:WGS – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period last year, the business posted ($0.23) earnings per share. Research analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System raised its holdings in GeneDx by 2.1% in the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock worth $728,000 after acquiring an additional 113 shares during the last quarter. Cerity Partners LLC raised its holdings in GeneDx by 6.0% in the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock worth $329,000 after acquiring an additional 142 shares during the last quarter. Main Management ETF Advisors LLC raised its holdings in GeneDx by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after acquiring an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after acquiring an additional 181 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on WGS shares. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the company a “buy” rating in a report on Tuesday, May 5th. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a report on Monday, February 23rd. Craig Hallum reiterated a “buy” rating and set a $85.00 target price on shares of GeneDx in a report on Tuesday, May 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Check Out Our Latest Stock Analysis on GeneDx

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

Positive Sentiment: Director Keith A. Meister kept buying shares, including 165,000 shares on May 13, 140,000 shares on May 14, and 46,273 shares on May 15, signaling strong insider confidence in GeneDx’s outlook and helping support the stock. Insider trade filing
Neutral Sentiment: GeneDx received an average brokerage recommendation of “Moderate Buy,” suggesting Wall Street still sees upside despite the recent volatility. Brokerage recommendation article
Negative Sentiment: A legal update from Pomerantz LLP said it is investigating claims on behalf of GeneDx investors, adding overhang from possible shareholder litigation after the company’s recent results. Pomerantz investigation article
Negative Sentiment: Another law firm, Levi & Korsinsky, announced a securities investigation tied to GeneDx’s Q1 revenue miss and reduced full-year guidance, reinforcing concerns that the post-earnings selloff may not be over. Levi & Korsinsky investigation article
Negative Sentiment: An analyst note cut GeneDx’s price target sharply to $98.94, highlighting a more cautious view after the company’s disappointing quarter. Price target cut article

About GeneDx

(Get Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.